Title:
プロゲストーゲンの肺送達方法
Document Type and Number:
Japanese Patent JP6693009
Kind Code:
B2
Abstract:
The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-OHPC) powder and the method of producing the formulation produces paritcles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-OHPC as taught herein may be used to reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (MAPK) activity. The 17-OHPC powder formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto- immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) and/or fluticasone with 17-OPHC.
More Like This:
Inventors:
Lee, Chang
Do, Tao Tom
Do, Tao Tom
Application Number:
JP2018534490A
Publication Date:
May 13, 2020
Filing Date:
September 21, 2016
Export Citation:
Assignee:
Shen Chun Evergreen Therapeutics Company Limited
International Classes:
A61K31/57; A61K9/12; A61K9/14; A61K9/72; A61K31/569; A61K31/58; A61P5/44; A61P11/08
Foreign References:
| US20110262502 |
Other References:
European Journal of Pharmaceutics and Biopharmaceutics,2006年,Vol.62,pp.1-16
Attorney, Agent or Firm:
Isono International Patent and Trademark Office